Understand the source comparison
Best Peptides for Concussion Healing: Evidence Comparison
Cerebrolysin BDNF pathway activation, neurotrophic factor delivery Meta-analysis: 15–20% cognitive improvement vs placebo (n=839, moderate-severe TBI) 30–50ml daily × 10–21 days IV infusion Requires clinical administration; no at-home protocol P21 CNTF recepto
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF pathway activation, neurotrophic factor delivery
- Meta-analysis: 15–20% cognitive improvement vs placebo (n=839, moderate-severe TBI)
- 30–50ml daily × 10–21 days
- IV infusion
- Requires clinical administration; no at-home protocol
- P21
- CNTF receptor agonist, synaptic plasticity enhancement
- Preclinical only (40% memory improvement in rodent TBI models)
- 1–5mg 2–3×/week
- Subcutaneous injection
- No human TBI trials; dosing extrapolated from Alzheimer's research
- Dihexa
- HGF mimetic, synaptogenesis via c-Met signaling
- Preclinical only (potency 7–10M× BDNF in rodent models)
- 0.5–2mg daily
- Oral or subcutaneous
- No human trials; optimal TBI dosing unknown
- Thymalin
- Immune modulation, cytokine regulation
- Observational (Russian literature, small cohorts)
- 10mg daily × 5–10 days
- Intramuscular injection
- Limited Western trial data; evidence quality lower
- KPV
- NF-κB inhibition, microglial anti-inflammatory effects
- In vitro only (50–60% cytokine reduction in microglial cultures)
- 500mcg–2mg daily
- Subcutaneous or oral
- No in vivo TBI data; CNS penetration assumed but not confirmed
- Professional Assessment
- Cerebrolysin has the strongest clinical evidence for moderate-severe TBI but requires IV administration. P21 and Dihexa show mechanistic promise but lack human trial validation. Anti-inflammatory peptides (Thymalin, KPV) address chronic neuroinflammation but aren't specific to acute injury repair.